|
PEX5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.76647626818294E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.02797803392241E-12 |
| Normal-vs-Stage2 |
8.577900E-03 |
| Normal-vs-Stage3 |
9.87740000901738E-10 |
| Normal-vs-Stage4 |
7.6764999912271E-09 |
| Stage1-vs-Stage2 |
4.483800E-03 |
| Stage1-vs-Stage3 |
5.428400E-01 |
| Stage1-vs-Stage4 |
5.387600E-01 |
| Stage2-vs-Stage3 |
6.822200E-03 |
| Stage2-vs-Stage4 |
1.118040E-02 |
| Stage3-vs-Stage4 |
9.070000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.9349192227387E-12 |
| Normal-vs-AfricanAmerican |
2.0554000000006E-05 |
| Normal-vs-Asian |
2.32229999996836E-06 |
| Caucasian-vs-AfricanAmerican |
9.253800E-01 |
| Caucasian-vs-Asian |
4.600400E-01 |
| AfricanAmerican-vs-Asian |
5.481800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
4.16729983854225E-10 |
| Normal-vs-Female |
3.64609453740172E-11 |
| Male-vs-Female |
4.526200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.04409814127848E-11 |
| Normal-vs-Age(41-60Yrs) |
5.57449997273807E-09 |
| Normal-vs-Age(61-80Yrs) |
1.04119999955188E-07 |
| Normal-vs-Age(81-100Yrs) |
2.675600E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.247400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.147600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.922600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.218600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.195800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.605000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.702000E-03 |
| Classical-VS-Follicular |
9.369000E-01 |
| Classical-VS-Other |
6.007700E-02 |
| Classical-VS-Normal |
2.17080020625815E-10 |
| Tall-VS-Follicular |
3.524100E-03 |
| Tall-VS-Other |
7.124800E-01 |
| Tall-VS-Normal |
3.73360231620268E-11 |
| Follicular-VS-Other |
1.190620E-01 |
| Follicular-VS-Normal |
2.08879999996636E-06 |
| Other-VS-Normal |
1.816570E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.08880000015965E-07 |
| Normal-vs-N1 |
3.94972943240646E-12 |
| N0-vs-N1 |
1.001130E-03 |
|
|
